Relationship of Vasoactive Peptide Levels to Portal Pressure and Patient Outcomes in Patients With Hepatic Cirrhosis - Full Text View

Relationship of Vasoactive Peptide Levels to Portal Pressure and Patient Outcomes in Patients With Hepatic Cirrhosis

This study has been completed.

Sponsored by:	Bayside Health
Information provided by:	Bayside Health
ClinicalTrials.gov Identifier:	NCT00163631

Purpose

Investigate vasoactive medicators in portal hypertension on stored sera

Condition

Portal Hypertension

MedlinePlus related topics:

Cirrhosis High Blood Pressure

U.S. FDA Resources

Study Type:	Observational
Study Design:	Natural History, Cross-Sectional, Defined Population, Retrospective Study

Official Title:	Relationship of Vasoactive Peptide Levels to Portal Pressure and Patient Outcomes in Patients With Hepatic Cirrhosis

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00163631

Locations


Australia, Victoria
	Alfred Hospital
	Melbourne, Victoria, Australia, 3181

Sponsors and Collaborators

Bayside Health

Investigators


Principal Investigator:	William W Kemp, MBBS FRACP	The Alfred

More Information

Study ID Numbers:	4104
First Received:	September 11, 2005
Last Updated:	October 3, 2006
ClinicalTrials.gov Identifier:	NCT00163631
Health Authority:	Australia: Human Research Ethics Committee

Study placed in the following topic categories:

Liver Diseases

Digestive System Diseases

Fibrosis

Vascular Diseases

Hypertension, Portal

Liver Cirrhosis

Portal hypertension

Hypertension

Additional relevant MeSH terms:

Pathologic Processes

Cardiovascular Diseases

ClinicalTrials.gov processed this record on September 19, 2008